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Abstract
Background—Cigarette smoking negatively affects kidney function. Genetic variants in the
nicotinic acetylcholine receptors genes (nAChRs) have been associated with nicotine dependence,
and are likely to influence renal function and related traits. While each single variant may only
exert a small effect, the joint contribution of multiple variants to the risk of disease could be
substantial.
Methods—Using a gene-family approach, we investigated the joint association of sixty-one
tagging SNPs in seven genes encoding the nicotinic acetylcholine receptors with kidney function
in 3,620 American Indians participating in the Strong Heart Family Study, independent of known
risk factors. Kidney function was evaluated by estimated glomerular filtration rate (eGFR), urinary
albumin/creatinine ratio (UACR), albuminuria and chronic kidney disease (CKD). The joint
impact of smoking-related variants was assessed using the weighted truncated product method.
Results—Multiple SNPs showed marginal individual effect on renal function variability, only a
few survive multiple comparison correction. In contrast, a gene-family analysis considering the
joint impact of all 61 SNPs reveals significant associations of the nAChR gene family with kidney
function variables including eGFR, UACR, and albuminuria (all P's≤0.0001) after adjusting for
established risk factors including cigarette smoking.
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Conclusions—Genetic variants in nAChRs genes jointly contribute to renal function or kidney
damage in American Indians. The effects of these genetic variants on kidney function or damage
are independent of traditional risk factors including cigarette smoking per se.
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Introduction
Chronic kidney disease (CKD) is a complex trait characterized by the progressive loss of
renal function, manifested by a decline in the glomerular filtration rate (GFR) and the onset
of abnormal albuminuria. The pathogenesis of CKD involves genes and environment as well
as gene-environment interactions.1 Genome-wide association studies (GWAS) have
identified over 30 genetic variants influencing interindividual variation in renal function,2-5
but these polymorphisms collectively only explain a small proportion of the estimated
heritability for renal function or CKD. It is well accepted that complex traits, such as CKD
and renal function, are regulated by many genes, each of which only has a small to moderate
individual effect, but their joint impact on disease susceptibility could be substantial.6 Thus,
testing each SNP one at a time often results in low statistical power in genetic analysis of
complex traits. In contrast, statistical methods taking into account the joint contribution of
multiple variants in one or more biological pathways may capture a large proportion of the
associated genetic variants, and thus should have a higher power than single-gene analysis in
dissecting the complex genetic architecture of renal function and its related disorders.
Cigarette smoking is an independent risk factor for the development of proteinuria,7 CKD
and its progression,8 and end-stage renal disease (ESRD).9 American Indians have the
highest prevalence of cigarette smoking among all US groups,10 and also suffer from high
rates of CKD.11 Epidemiologic studies have demonstrated that, cigarette smoking
significantly increases the risk of CKD12 and there was a dose-response relationship
between number of cigarettes smoked and the levels of proteinuria13 and glomerular
filtration rate (eGFR).14 Cigarette smoking may also accelerate the progression of CKD of
diverse etiologies including diabetes, 15, 16 hypertension17 and post kidney transplantation.18
However, the biological mechanisms linking cigarette smoking to reduced renal function or
CKD remain to be determined. Identifying independent preventable risk factors will provide
not only novel insights into the pathophysiological mechanisms but also optimal strategies
to mitigate the loss of renal function, thereby preventing or slowing down CKD or eventual
kidney failure.
Nicotine, the major bioactive component of cigarette smoke, may cause renal damage by
increasing blood pressure19 or renal oxidative stress.20 At the molecular level, nicotine acts
by binding to nicotinic acetylcholine receptors (nAChRs), a superfamily of ligand-gated ion
channels that is widely present within neuronal and non-neuronal cell types.21 Genetic
polymorphisms in the nAChRs genes have been shown to affect renal function in a mouse
model.22 However, limited research has investigated the potential impact of nAChRs
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variants on renal function variability in human. Moreover, existing studies focused on single
gene analysis, which is less powerful in detecting small genetic effect and cannot capture the
joint contribution of multiple genes. The goal of this study is therefore to conduct a gene-
family analysis to examine the joint impact of 61 tagging SNPs in seven nAChRs genes on
kidney function in a large, well-characterized population of American Indians participating
in the Strong Heart Family Study (SHFS).
Methods
Study population
The Strong Heart Family Study (SHFS) is a multicenter, family-based prospective study
designed to identify genetic factors for cardiovascular disease (CVD), diabetes and their risk
factors in American Indians. A total of 3,665 tribal members (aged 18 years and older) from
94 multiplex families residing in Arizona (AZ), North and South Dakota (DK) and
Oklahoma (OK) were recruited and examined between 2001 and 2003. Detailed descriptions
of the SHFS protocols for phenotype collection have been described previously.23, 24 All
participants received a personal interview to collect data on demographic characteristics,
medical history and lifestyle risk factors including smoking, alcohol consumption, diet and
physical activity. A physical examination was given to each participant, including
anthropometric and blood pressure measurements and an examination of the heart and lungs.
Fasting blood sample was obtained to measure lipid levels, fasting glucose, fasting insulin
and inflammatory biomarkers. A spot urine sample was collected to measure albumin and
creatinine. Laboratory methods were reported previously.23, 25 All participants have given
informed consent for genetic study of cardiovascular disease, diabetes and associated risk
factors. The SHFS protocol was approved by the Institutional Review Boards from the
Indian Health Service and the participating centers.
Assessments of renal function or kidney damage
Methods for the measurement of urinary albumin and creatinine have been described
previously.26 In brief, serum and urine creatinine were measured by the picric acid
method.27 Urine albumin content was measured by a sensitive nephelometric technique.28
Serum and urine creatinine were assayed by a kinetic alkaline picrate method and urine
albumin by a sensitive nephelometric method, both on the Hitachi 717 platform (Roche
Diagnostics, Indianapolis, IN). Urine albumin excretion was estimated as urinary albumin/
creatinine ratio (UACR, mg/g) and estimated glomerular filtration rate (eGFR) was
calculated using the Modified Diet and Renal Disease (MDRD) equation.29 Renal function
was assessed using eGFR, whereas UACR was used as a measure of kidney damage. Based
on UACR values, participants were classified as either normal (UACR <30 mg/g), or
microalbuminuria (30 ≤ UACR < 300 mg/g) or macroalbuminuria (UACR ≥ 300 mg/g).
CKD was defined as eGFR < 60 mL/min/1.73m2 or UACR ≥ 30mg/g.30
Measurement of risk factors
Body weight (kg) and height (cm) were measured when participants wore light clothes and
no shoes by trained research staff. Body mass index (BMI) was calculated by dividing
weight in kilograms by the square of height in meters. Waist circumference was measured at
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the level midway between the lowest rib and the uppermost iliac crest with the subjects
standing. Hip circumference was measured at the level of widest circumference over greater
trochanters with the legs close together. Waist/hip ratio (WHR) was calculated as waist
circumference divided by hip circumference. Cigarette smoking was assessed via
questionnaire and classified as current smokers, former smokers and never smokers. Current
smokers reported smoking 100 or more cigarettes in their lifetime and were currently
smoking every day or some days. Former smokers are those who had smoked 100 or more
cigarettes but were no longer smoking. Never smokers are those who smoked fewer than
100 cigarettes or never smoked in their life time. Based on the history of alcohol
consumption, subjects were categorized into current drinkers, former drinkers and never
drinkers. Physical activity was assessed by the mean number of steps per day calculated by
averaging the total number of steps recorded each day during the 7-day period. Hypertension
was defined as blood pressure levels of 140/90 mm Hg or higher or use of antihypertensive
medications. According to the 1997 American Diabetes Association (ADA) criteria,31
diabetes was defined as fasting plasma glucose ≥7.0 mmol/L) or receiving insulin or oral
hyperglycemic treatment. Impaired fasting glucose (IFG) was defined as a fasting glucose of
6.1-7.0 mmol/L. Fasting glucose <6.1 mmol/L was defined as normal.
TagSNPs selection and genotyping
A total of 3,665 SHFS participants were genotyped for sixty-one tagSNPs in seven
candidate genes from the nAChRs gene family (CHRNA3-A6, CHRNB2-B4). These genes
were frequently reported to be associated with cigarette smoking in previous studies. For
tagSNP selection within each candidate gene, we used the computer program Haploview
4.2 32 with an r2 threshold of 0.80 for linkage disequilibrium (LD). The following criteria
were also considered: minor allele frequency (MAF>5%), SNP location (i.e., coding region)
and Illumina design scores (quantifying how likely a SNP can be genotyped). SNPs that
could not be tagged (i.e., singletons) were included as long as their design score was greater
than 0.15. All genotyping was done at the Texas Biomedical Research Institute using the
Illumina VeraCode technology (Illumina, Inc., San Diego, CA). The average genotyping call
rates were 98% for the chosen SNPs, and sample success rate was 99.5%. Details of the 61
tagSNPs were shown in Table S1.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) of each SNP was tested by PLINK using genotype
data of founders. Descriptive analysis of continuous variables was performed using
generalized estimating equation (GEE), which accounts for correlations among family
members. Chi-square test was used for categorical variables. Prior to statistical analyses,
continuous variables were log-transformed to improve normality. Participants with missing
information on smoking status (N=15) or renal function (N=30) were excluded from further
analyses. All analyses were done using R 3.0.1 (R Development Core Team) and SAS 9.3
(SAS Institute Inc., Cary, NC).
Single SNP analysis—We first tested the association of each SNP with renal function
variables, including eGFR (continuous), UACR (continuous), albuminuria
(microalbuminuria vs. macroalbuminuria vs. normal), and CKD (yes/no) using multivariate
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GEE, adjusting for age, sex, study center, BMI, history of diabetes or hypertension or CVD,
smoking status (ever smoker vs. never), alcohol drinking (current vs. former vs. never),
physical activity level, and socioeconomic status. To examine whether population
stratification will affect our results, we further validated the results by family-based
association test (FBAT) using FBAT.33 Multiple testing was corrected using the Storey's q-
value method.34
Gene-based and gene-set analysis—Association of a candidate gene (including all
SNPs within the gene) with each measure of kidney function was assessed by combining P-
values from single SNP association analysis. This was done using a weighted truncated
product method (wTPM)35 with effect size of each single SNP analysis as the weight. A
gene-set analysis was then performed by combing P-value of each candidate gene obtained
from gene-based analysis, including all seven genes in the nAChRs gene family. Detailed
methods for gene-based and gene-set analyses have been described previously.36
Sensitivity analyses—Renal function and CKD are strongly associated with CVD,37, 38
diabetes39 or hypertension.40 To examine their potential impact on our results, we conducted
sensitivity analyses by excluding participants with CVD (N=153), diabetes (N=820) or
hypertension (N=1,205). To investigate whether the observed gene-family associations are
primarily driven by the most significant SNPs in single gene analysis, we performed
secondary analyses by removing SNPs showing the most significant association with renal
variables.
Results
Baseline characteristics of the study participants
Table 1 presents baseline characteristics of study participants according to smoking status.
Compared to never smokers, ever smokers (current plus former smoker) were older, more
likely to be males, more likely to be centrally obese, and had higher levels of total
cholesterol and triglyceride. No difference was observed for other risk factors between never
and ever smokers.
Association of individual SNP with renal function variables
The pattern of linkage disequilibrium (LD) and allele frequencies of the studied SNPs
stratified by study center (AZ, OK and DK) were described previously.36 It appears that
subjects from different centers have heterogeneous genetic background. However, this
should not be a concern for our analysis because we validated our results using family-based
association test (FBAT), which are robust to population substructure.33
Results of single SNP association analysis are listed in Table 2. After adjustments for
covariates and multiple testing, eight SNPs (six in CHRNA3, two in CHRNA5, all p's
≤0.0006) were significantly associated with eGFR, and one SNP in CHRNB4 (rs1996371,
p=0.006) was significantly associated with UACR. No SNP was individually associated
with CKD or albuminuria. Effect sizes of the SNPs showing significant associations were
shown in Table S2.
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Gene-based and gene-set association with kidney function
Gene-based analysis indicated that, after adjusting for multiple testing, the CHRNA3 gene
was significantly associated with eGFR (P≤ 0.0001), UACR (P≤0.0001) and albuminuria (P
≤ 0.002). The CHRNA5 gene was significantly associated with eGFR and UACR (both P's
≤0.0001), and the CHRNB4 gene was significantly associated with eGFR (P≤0.0001) and
albuminuria (P≤0.002). In addition, the CHRNA4 gene was associated with albuminuria
(P≤0.004). Gene-family analysis comprising all seven genes showed significant associations
with eGFR, UACR and albuminuria (all p's ≤ 0.0001). No association was observed for
CKD at either the gene-level or the pathway-level. Results for gene- and gene-family
analyses are shown in Table 3.
Results of sensitivity analysis
Kidney disease is strongly related to diabetes, hypertension and CVD. To examine whether
and how these chronic disorders influence our results, we conducted sensitivity analyses by
stratifying statistical analyses according to the status of diabetes, hypertension or CVD. The
observed gene-family associations with eGFR, UACR, or albuminuria persisted among
participants with neither (Table S3) or one of these chronic conditions (Tables S4-6). It
shows that excluding participants with hypertension and/or CVD has no or little effect on
the observed associations with the four renal phenotypes, but excluding diabetic patients
resulted in different results. For instance, the gene-family association with CKD was
statistically nonsignificant in analysis of all study participants (though diabetes was adjusted
in the statistical model), but after excluding participants with diabetes, the gene-family
association became highly significant (P<0.0001). This may suggest a larger impact of
diabetes on the relationship between smoking variants and kidney function. In addition,
removing the most significant SNP from gene-set analysis did not change our results,
indicating that the observed gene-family associations may not be driven by the SNP showing
the most significant association with eGFR, UACR, CKD or albuminuria Table S7). The
gene-based and gene-family associations using P values obtained by FBAT are listed in
Table S8, which indicates that population structure has no appreciable effect on our results.
Furthermore, additional adjustments for smoking status or pack-years did not change the
results of gene- or gene-family analyses, suggesting that the observed associations are
independent of smoking per se.
Discussion
In this study, we demonstrated that multiple SNPs in the nAChRs gene family, each of
which has a small individual effect, jointly contribute to kidney function or renal damage
among American Indians participating in the Strong Heart Family Study. This association is
independent of known risk factors, including cigarette smoking per se. Although the precise
mechanisms underlying the observed association await further research, the identified
genetic associations or related pathways highlight novel genetic mechanisms involved in the
regulation of renal function in this minority population.
Several aspects of our study merit comments. First, consistent with previous research,41 our
results demonstrated that a single SNP may only confer a small or marginal individual effect
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on kidney function, but the joint effect of multiple SNPs within a gene or a biological
pathway on disease susceptibility could be large. For example, none of the examined SNPs
in CHRNA3 was individually associated with UACR or albuminuria, but gene-based
analysis revealed a significant association of this gene with both UACR and albuminuria.
Similar phenomenon was also observed for other genes, e.g., CHRNA4, CHRNA5 and
CHRNB4. Gene-family analysis demonstrates that the 61 examined SNPs as a whole jointly
contribute to renal function phenotypes including eGFR, UACR and albuminuria. This
reinforces the emerging evidence that it is the cumulative effects of many loci, rather than
the individual effect of a single variant, that underlies the susceptibility to disease. Second,
multiple variants have been reported to be associated with CKD or related traits,42 but none
of the SNPs examined in our study was previously associated with kidney function,
probably due to the unique genetic background of American Indians, or lack of sufficient
genotyping or sequencing coverage of the nAChRs gene regions in previous studies. Third,
although eGFR, UACR, albuminuria and CKD are highly correlated clinical phenotypes,
their genetic etiologies may not be exactly the same. This is supported by the incomplete
overlapping in genetic profiles of different traits at the three genetic levels (i.e., single SNP,
gene-based or gene-family). For example, the seven SNPs (Table 2) showing significant
associations with eGFR were not associated with UACR, or albuminuria or CKD. A SNP in
CHRNB4 (rs1996371) was associated with UACR, but not other phenotypes. At the gene-
level, the CHRNA3 gene was significantly associated with eGFR, UACR and albuminuria,
but not CKD, whereas the CHRNA5 gene was associated with eGFR and UACR, but not
CKD and albuminuria. Moreover, the joint association of all nAChRs variants in gene-
family analysis was statistically significant for eGFR, UACR and albuminuria, but not CKD,
again highlighting the potential different genetic etiologies underlying these complex traits.
In addition, it appears that diabetes has a large impact on the genetic association between
nAChRs variants and CKD, because results of gene-family analysis are different before and
after excluding participants with diabetes (Tables 3 and S4). Finally, the observed gene-
family associations are unlikely to be mediated by cigarettes smoking per se, because we
adjusted for smoking status in all statistical analyses.
While the link between cigarette smoking and renal function has been well established,12
biological pathways through which smoking negatively affects renal function remain
incompletely understood. It is possible that cigarette smoking influences renal function
through its effects on inflammation and/or oxidative stress,43 both of which have been
implicated in the pathogenesis of chronic renal failure or CKD.14 In a recent study, we have
shown that genetic variants in the same nAChRs genes included in the current analysis are
also associated with insulin resistance,36 a mechanism known to be involved in CKD.44
Moreover, it has long been appreciated that renal hemodynamics (i.e., arterial pressure,
glomerular filtration rat, and renal blood flow) are regulated by renal sympathetic nerve
activity, dysregulation of which may cause renal dysfunction.45, 46 Genetic variants in
nAChRs genes located on the postganglionic sympathetic nerve terminals could influence
renal hemodynamics, thereby contribute to the pathological effects of smoking on the
kidney. The association of nAChRs variants with kidney function or damage observed in our
study is independent of cigarette smoking per se, providing further support that cigarette
smoking may affect kidney function through its impact on neuronal nicotinic receptors.
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Our study has some limitations. Though we have controlled many potential confounders, we
cannot rule out the possibility of residual confounding by other unknown or unmeasured
factors. The cross-sectional design of our study precludes any causal inference. In addition,
our analyses were undertaken among a cohort of American Indians with high prevalence of
cigarette smoking and type 2 diabetes. It is unclear whether our results can be generalized to
other ethnic groups with different patterns of risk profiles. Moreover, low frequency and/or
rare variants may exhibit larger effects on disease phenotypes. In this study, we tagged six
low frequency SNPs but none was significantly associated with any of the renal variables.
Target resequencing or deep sequencing in future research should provide better chance to
capture potentially important low frequency or rare variants with large effects influencing
interindividual variability in renal function phenotypes.
In summary, this study provides initial evidence that multiple genetic variants in the
nAChRs gene family jointly contribute to kidney function, independent of traditional renal
risk factors. The impact of these genetic variants on the susceptibility to renal function may
not be mediated by cigarette smoking per se. Our results may provide novel insights into
disease pathophysiology and also valuable information for personalized prevention or
intervention in American Indians who suffer from increasingly high prevalence of diabetes
and kidney disease.
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Table 1
Characteristics of the study participants according to smoking status (n=3,620)
Ever smoker‡ (n=2,097) Never smoker (n=1,523) P*
(Mean ± SD or %) (Mean ± SD or %)
Age (years) 41.2±15.6 37.9±18.5 <0.0001
Male sex (%) 44.5 33.9 <0.0001
Type 2 diabetes (%) 24.2 21.0 0.49
Hypertension (%) 34.2 31.9 0.13
Cardiovascular disease (%) 4.5 3.9 0.29
Body mass index (kg/m2) 32.2±7.9 32.3±7.9 0.72
Waist circumference (cm) 105.3±18.2 103.6±19.1 0.2
Waist/hip ratio 0.92±0.08 0.90±0.08 0.002
Percent body fat 36.8±10.0 38.0±10.4 0.62
Systolic blood pressure (mmHg) 123.4±17.0 121.7±17.3 0.39
Diastolic blood pressure(mmHg) 76.8±10.9 75.5±11.5 0.17
High-density lipoprotein (mg/dL) 50.5±14.5 51.3±14.7 0.44
Low-density lipoprotein (mg/dL) 99.4±29.7 96.4±28.9 0.3
Plasma hsCRP (mg/L) 7.0±9.2 6.8±9.9 0.45
Total cholesterol (mg/dL) 183.4±38.6 177.2±34.8 0.006
Total triglyceride (mg/dL) 177.2±197.3 155.4±123.8 0.01
Fasting glucose (mg/dL) 115.8±52.7 112.1±52.8 0.52
Insulin (uU/mL) 18.7±20.2 18.8±20.4 0.74
eGFR (ml/min/1.73m2) 99.1±27.2 101.8±30.1 0.96
UACR (mg/g)╪ 24.6 ±58.9 23.7±55.3 0.85
Chronic kidney disease (%) 20.6 20.8 0.08
Microalbuminuria (%) 13.7 13.3 0.69
Macroalbuminuria (%) 3.8 3.7 0.47
*
P values were obtained by GEE, adjusting for age and sex when appropriate
‡
Former plus current smokers
╪
Excluded outliers with UACR (UACR greater than mean+3SD, total exclusion =8)
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Table 3
Gene-based and gene-family associations of seven nAChRs genes with kidney function
using weighted truncated product method
Gene eGFR UACR CKD albuminuria
CHRNA3 0.0001 0.0001 0.5936 0.0022
CHRNA4 0.0304 0.3436 0.2760 0.0044
CHRNA5 0.0001 0.0001 0.2886 0.0290
CHRNA6 0.2451 0.6927 0.4334 0.2316
CHRNB2 0.1986 0.4552 0.2832 0.2260
CHRNB3 0.2006 0.0872 0.2320 0.1622
CHRNB4 0.0001 0.0180 0.6124 0.0020
The nAChRs gene family 0.0001 0.0001 0.2168 0.0001
P-values in bold indicate statistical significance after correction for multiple testing
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